Currently, EGFR tyrosine kinase inhibitors (EGFR-TKIs) are considered as the standard first-line treatment for patients with locally advanced or metastatic NSCLC harboring sensitizing EGFR mutations [8,9]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.